Company Quick10K Filing
Quick10K
United Guardian
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$18.89 5 $87
10-Q 2019-03-31 Quarter: 2019-03-31
10-K 2018-12-31 Annual: 2018-12-31
10-Q 2018-09-30 Quarter: 2018-09-30
10-Q 2018-06-30 Quarter: 2018-06-30
10-Q 2018-03-31 Quarter: 2018-03-31
10-K 2017-12-31 Annual: 2017-12-31
10-Q 2017-09-30 Quarter: 2017-09-30
10-Q 2017-06-30 Quarter: 2017-06-30
10-Q 2017-03-31 Quarter: 2017-03-31
10-K 2016-12-31 Annual: 2016-12-31
10-Q 2016-09-30 Quarter: 2016-09-30
10-Q 2016-06-30 Quarter: 2016-06-30
10-Q 2016-03-31 Quarter: 2016-03-31
10-K 2015-12-31 Annual: 2015-12-31
10-Q 2015-09-30 Quarter: 2015-09-30
10-Q 2015-06-30 Quarter: 2015-06-30
10-Q 2015-03-31 Quarter: 2015-03-31
10-K 2014-12-31 Annual: 2014-12-31
10-Q 2014-09-30 Quarter: 2014-09-30
10-Q 2014-06-30 Quarter: 2014-06-30
10-Q 2014-03-31 Quarter: 2014-03-31
10-K 2013-12-31 Annual: 2013-12-31
8-K 2019-05-15 Shareholder Vote, Regulation FD, Exhibits
8-K 2019-05-09 Earnings, Exhibits
8-K 2019-03-21 Earnings, Exhibits
8-K 2019-03-21 Accountant, Exhibits
8-K 2018-11-29 Regulation FD, Exhibits
8-K 2018-11-08 Earnings, Exhibits
8-K 2018-08-08 Earnings, Exhibits
8-K 2018-05-16 Shareholder Vote
8-K 2018-05-10 Earnings, Exhibits
TYL Tyler Technologies 8,270
MTDR Matador Resources 2,320
BRKL Brookline Bancorp 1,240
CNSL Consolidated Communications Holdings 358
INSUU Insurance Acquisition 138
INMB INmune Bio 112
SMRT Stein Mart 44
UNAM Unico American 32
EWD FSP 303 East Wacker Drive 0
MMMB Mamamancini's Holdings 0
UG 2019-03-31
Part I. Financial Information
Item 1. Condensed Financial Statements.
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Item 4. Controls and Procedures
Part II - Other Information
Item 1.Legal Proceedings
Item 1A.Risk Factors
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds
Item 3.Defaults Upon Senior Securities
Item 4.Mine Safety Disclosures
Item 5.Other Information
Item 6.Exhibits
EX-31.1 exh_311.htm
EX-31.2 exh_312.htm
EX-32 exh_32.htm

United Guardian Earnings 2019-03-31

UG 10Q Quarterly Report

Balance SheetIncome StatementCash Flow

10-Q 1 f10q_050819p.htm FORM 10-Q

 

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2019

 

 

TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to _________

 

 

Commission File Number: 1-10526

 

 

UNITED-GUARDIAN, INC. .

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware   11-1719724
(State or Other Jurisdiction of   (I.R.S. Employer Identification No.)
Incorporation or Organization)    

 

  230 Marcus Boulevard, Hauppauge, New York 11788  
  (Address of Principal Executive Offices)  
     
  (631) 273-0900  
  (Registrant’s Telephone Number)  

 

  N/A  
  (Former name, former address and former fiscal year, if changed since last report)  

 

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒   No ☐

 

Cover Page 1 of 2

 

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

 

  Large accelerated filer  
  Non-accelerated filer   (Do not check if a smaller reporting company)
  Accelerated filer  
  Smaller reporting company   ☒ 
  Emerging growth company  


If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)

 

  Yes ☐ No

 

Securities registered pursuant to Section 12(b) of the Act:

     
Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, $0.10 par value per share UG NASDAQ Global Market

 

The registrant had 4,594,319 shares of common stock, $.10 par value per share, outstanding at May 1, 2019.

 

Cover Page 2 of 2

 

 

UNITED-GUARDIAN, INC.

INDEX TO FINANCIAL STATEMENTS

 

  Page No.
   
Part I. FINANCIAL INFORMATION  
   
Item 1 - Condensed Financial Statements (unaudited unless indicated otherwise):  
   
Statements of Income - Three months ended March 31, 2019 and 2018 2
   
Balance Sheets - March 31, 2019 (unaudited) and December 31, 2018 (audited) 3-4
   
Statements of Changes in Stockholder’s Equity – Three months ended March 31, 2019 and 2018 5
   
Statements of Cash Flows –Three months ended March 31, 2019 and 2018 6
   
Notes to Condensed Financial Statements 7-14
   
Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations 14-20
   
Item 3 - Quantitative and Qualitative Disclosures About Market Risk 20
   
Item 4 - Controls and Procedures 20-21
   
Part II. OTHER INFORMATION  
   
Item 1 - Legal Proceedings 21
   
Item 1A - Risk Factors 21
   
Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds 21
   
Item 3 - Defaults Upon Senior Securities 21
   
Item 4 - Mine Safety Disclosures 21
   
Item 5 - Other Information 21
   
Item 6 - Exhibits 21
   
Signatures 22

 

Page 1 of 22

 

 

Part I. FINANCIAL INFORMATION

 

ITEM 1. Condensed Financial Statements.

 

UNITED-GUARDIAN, INC.

 

STATEMENTS OF INCOME

(UNAUDITED)

 

   THREE MONTHS ENDED
MARCH 31,
   2019  2018
Sales:          
Gross sales  $3,452,894   $3,666,947 
Sales allowances and returns   (170,870)   (147,435)
Net Sales   3,282,024    3,519,512 
           
Costs and expenses:          
Cost of sales   1,390,051    1,450,931 
Operating expenses   546,962    524,114 
Research and development   98,659    101,664 
Total costs and expenses   2,035,672    2,076,709 
Income from operations   1,246,352    1,442,803 
           
Other income (expense):          
Investment income   44,167    46,782 
Net gain (loss) on marketable securities   257,194    (135,150)
Loss from trade-in of equipment   —      (12,837)
Total other income (expense)   301,361    (101,205)
Income before provision for income taxes   1,547,713    1,341,598 
           
Provision for income taxes   325,019    281,736 
           
Net income  $1,222,694   $1,059,862 
           
Earnings per common share
(basic and diluted)
  $0.27   $0.23 
           
Weighted average shares – basic and diluted   4,594,319    4,594,319 

 

See notes to condensed financial statements

 

Page 2 of 22

 

 

UNITED-GUARDIAN, INC.

 

BALANCE SHEETS

 

ASSETS

 


 
 
 
MARCH 31,
2019
 
 
DECEMBER 31,
2018
   (UNAUDITED)  (AUDITED)
Current assets:          
Cash and cash equivalents  $499,256   $550,135 
Marketable securities   9,448,931    7,622,196 
Accounts receivable, net of allowance for doubtful accounts of $16,895 at March 31, 2019 and December 31, 2018   1,604,860    1,672,567 
Inventories (net)   1,324,771    1,482,151 
Prepaid expenses and other current assets   227,432    159,364 
Prepaid income taxes   36,524    200,687 
Total current assets   13,141,774    11,687,100 
           
           
Property, plant and equipment:          
Land   69,000    69,000 
Factory equipment and fixtures   4,412,216    4,406,174 
Building and improvements   2,808,532    2,801,582 
Total property, plant and equipment   7,289,748    7,276,756 
Less: accumulated depreciation   6,487,230    6,448,831 
Total property, plant and equipment (net)   802,518    827,925 
           
Other assets (net)   25,941    29,647 
           
TOTAL ASSETS  $13,970,233   $12,544,672 

 

See notes to condensed financial statements

 

 

Page 3 of 22

 

 

UNITED-GUARDIAN, INC.

 

BALANCE SHEETS

(continued)

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

   MARCH 31,
2019
  DECEMBER 31,
2018
Current liabilities:  (UNAUDITED)  (AUDITED)
Accounts payable  $142,492   $186,797 
Accrued expenses   1,276,951    1,040,635 
Dividends payable   138,719    138,719 
Total current liabilities   1,558,162    1,366,151 
           
Deferred income taxes (net)   264,439    253,583 
           
Commitments and contingencies          
           
Stockholders’ equity:          
Common stock $.10 par value; 10,000,000 shares authorized; 4,594,319 shares issued and outstanding at March 31, 2019 and December 31, 2018   459,432    459,432 
Retained earnings   11,688,200    10,465,506 
Total stockholders’ equity   12,147,632    10,924,938 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $13,970,233   $12,544,672 

 

See notes to condensed financial statements

 

 

 

 

 

Page 4 of 22

 

 

UNITED-GUARDIAN, INC.

 

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(UNAUDITED)

 

THREE MONTHS ENDED MARCH 31, 2019

 

   Common stock  Accumulated
Other
Comprehensive
  Retained   
   Shares  Amount  Income  Earnings  Total
Balance, January 1, 2019   4,594,319   $459,432    —     $10,465,506   $10,924,938 
                          
Net income   —      —      —      1,222,694    1,222,694 
                          
Balance, March 31, 2019   4,594,319   $459,432    —     $11,688,200   $12,147,632 

 

THREE MONTHS ENDED MARCH 31, 2018

 

   Common stock  Accumulated
Other
Comprehensive
  Retained   
   Shares  Amount  Income  Earnings  Total
Balance, January 1, 2018   4,594,319   $459,432   $466,025   $10,471,185   $11,396,642 
                          
Reclassification of accumulated other comprehensive income to retained earnings in accordance with ASU 2016-01 (See Note 5 )             (466,025)   466,025    —   
                          
Net income   —      —      —      1,059,862    1,059,862 
                          
Balance, March 31, 2018   4,594,319   $459,432   $—     $11,997,072   $12,456,504 

 

See notes to condensed financial statements

 

 

 

Page 5 of 22

 

 

UNITED-GUARDIAN, INC.

 

STATEMENTS OF CASH FLOWS
(UNAUDITED)

 

   THREE MONTHS ENDED
MARCH 31,
   2019  2018
Cash flows from operating activities:          
Net income  $1,222,694   $1,059,862 
Adjustments to reconcile net income to net cash provided by operating activities:          
Depreciation and amortization   42,105    49,152 
Net (gain) loss on marketable securities   (257,194)   135,150 
Realized loss from trade-in of equipment   —      12,837 
Deferred income taxes   10,856    (28,381)
Decrease (increase) in operating assets:          
Accounts receivable   67,707    93,628 
Inventories   157,380    (88,647)
Prepaid expenses and other current and non-current assets   (68,068)   (51,260)
Prepaid income taxes   164,163    —   
(Decrease) increase in operating liabilities:          
Accounts payable   (44,305)   (69,586)
Income taxes payable   —      310,117 
Accrued expenses   236,316    247,309 
Net cash provided by operating activities   1,531,654    1,670,181 
           
Cash flows from investing activities:          
Acquisition of property, plant and equipment   (12,992)   (26,500)
Purchase of marketable securities   (6,049,914)   (1,297,254)
Proceeds from sales of marketable securities   4,480,373    —   
Net cash used in investing activities   (1,582,533)   (1,323,754)
           
Net (decrease) increase in cash and cash equivalents   (50,879)   346,427 
Cash and cash equivalents at beginning of period   550,135    724,721 
Cash and cash equivalents at end of period  $499,256   $1,071,148 
           
Non-cash investing activities:          
Cost of equipment traded in (net)  $—     $39,837 
           
Supplemental disclosure of cash flow information          
Taxes paid  $150,000   $—   

 

See notes to condensed financial statements

 

Page 6 of 22

 

 

UNITED-GUARDIAN, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)

 

1.Nature of Business

 

United-Guardian, Inc. (the “Company”) is a Delaware corporation that, through its Guardian Laboratories division, conducts research, product development, manufacturing and marketing of cosmetic ingredients, personal and health care products, pharmaceuticals, medical products, and proprietary specialty industrial products.

 

2.Basis of Presentation

 

Interim condensed financial statements of the Company are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information, pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. In the opinion of management, all adjustments considered necessary for the fair presentation of financial statements for the interim periods have been included. The results of operations for the three-month period ended March 31, 2019 (also referred to as the “first quarter of 2019”) are not necessarily indicative of results that ultimately may be achieved for any other interim period or for the year ending December 31, 2019. The interim unaudited condensed financial statements and notes thereto should be read in conjunction with the audited condensed financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2018.

 

3.Use of Estimates

 

In preparing financial statements in accordance with US GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for bad debts, accrued distribution fees, outdated material returns, possible impairment of marketable securities, and the allocation of overhead to inventory.

 

4.Revenue Recognition

 

Effective January 1, 2018 the Company adopted ASC Topic 606 “Revenue from Contracts with Customers” using the modified retrospective method. Under the new guidance revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. Our principal source of revenue is product sales.

 

 

Page 7 of 22

 

 

Our gross revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration includes chargebacks from the United States Department of Veterans Affairs (‘VA”), rebates, distribution fees, and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on gross sales for a reporting period.

 

The Company recognizes revenue from sales of its personal care, medical, and industrial products when those products are shipped, as long as a valid purchase order has been received and future collection of the sale amount is reasonably assured. These products are shipped “Ex-Works” from the Company’s facility in Hauppauge, NY, and it is at this time that risk of loss and responsibility for the shipment passes to the customer. Sales of these products are deemed final, and there is no obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective.

 

The Company’s pharmaceutical products are shipped via common carrier upon receipt of a valid purchase order, with, in most cases, the Company paying the shipping costs. Sales of pharmaceutical products are final, and revenue is recognized at the time of shipment. Pharmaceutical products are returnable only at the discretion of the Company unless (a) they are found to be defective; (b) the product is damaged in shipping; or (c) the product is outdated (but not more than one year after their expiration date, which is a return policy which conforms to standard pharmaceutical industry practice). The Company estimates an allowance for outdated material returns based on prior year historical returns of their pharmaceutical products.

 

The Company does not make sales on consignment, and the collection of the proceeds of the sale of any of the Company’s products is not contingent upon the customer being able to sell the goods to a third party.

 

Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience. The Company has not experienced significant fluctuations between estimated allowances and actual activity.

 

The timing between recognition of revenue for product sales and the receipt of payment is not significant. Our standard credit terms, which vary depending on the customer, range between 30 and 60 days. We also use judgments as to our ability to collect outstanding receivables and provide allowances for the portion of receivables if collection becomes doubtful. As of March 31, 2019, and December 31, 2018 the allowance for doubtful accounts receivable was $16,895. Prompt pay discounts are offered to some customers; however, due the uncertainty of the customers taking the discounts, the discounts are recorded when they are taken.

 

The Company has distribution fee contracts with certain customers in connection with the sales to them of the Company’s products that entitle them to distribution-related fees. The Company estimates and records distribution fees due to these customers in sales returns and allowances.

 

Page 8 of 22

 

 

Disaggregated revenue by product class is as follows:

 

   Three months ended March 31,
   2019  2018
       
Personal Care  $1,651,722   $2,123,114 
Pharmaceutical   1,158,883    974,120 
Medical   611,802    540,470 
Industrial and other   30,487    29,243 
Gross Sales   3,452,894    3,666,947 
Less: Allowances and returns   (170,870)   (147,435)
Net Sales  $3,282,024   $3,519,512 

 

The Company’s personal care products are marketed worldwide by six marketing partners, of which U.S.-based Ashland Specialty Ingredients (“ASI”) purchases the largest volume. Approximately 18% of the Company’s total sales were to customers located outside of the United States in the first quarter of 2019, compared with approximately 17% in the first quarter of 2018.

 

Disaggregated revenue by geographic region is as follows:

 

   Three months ended March 31,
   2019  2018
United States*  $2,825,025   $3,056,809 
Other countries   627,869    610,138 
Gross Sales  $3,452,894   $3,666,947 

 

* Since all purchases by ASI are shipped to ASI’s warehouses in the U.S. they are reported as U.S. sales for financial reporting purposes. However, ASI has reported to the Company that approximately 80% of its sales in the first quarter of 2019 were to customers in other countries, with China representing approximately 50% of ASI’s sales of the Company’s products.

 

5.Marketable Securities

 

Marketable securities include investments in fixed income and equity mutual funds and Government securities with maturities greater than 3 months, which are reported at their fair values. Effective January 2018, the Company adopted Accounting Standards Update (“ASU”) 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities”. This amendment requires companies to measure equity investments at fair value with the changes in fair value recognized in net income.

 

In accordance with the implementation of the standard, the Company recognized a cumulative-effect adjustment, related to unrealized gains on marketable equity securities, to reduce accumulated other comprehensive income and increase retained earnings on January 1, 2018 by $466,025.

 

Page 9 of 22

 

 

The disaggregated net gains and losses on the marketable securities recognized in the income statement for the three months ended March 31, 2019 are as follows:

 

Net gains recognized during the period on marketable securities  $262,423 
Less: Net losses recognized during the period on marketable securities sold during the period   (5,229)
Unrealized gains recognized during the reporting period on marketable securities still held at the reporting date  $257,194 

 

The fair values of the Company’s marketable securities are determined in accordance with US GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the three-tier value hierarchy, as prescribed by US GAAP, which prioritizes the inputs used in measuring fair value as follows:

 

      Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

      Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

      Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

The Company’s available-for-sale securities, which comprise all the Company's marketable securities, are re-measured to fair value on a recurring basis and are valued using Level 1 inputs using quoted prices (unadjusted) for identical assets in active markets. The following tables summarize the Company’s investments:

 

March 31, 2019 (unaudited)  Cost  Fair Value  Unrealized gain
                
U.S Treasury Bills (Original maturities greater than three months, but less than one year)  $5,967,605   $5,967,605   $—   
Fixed income mutual funds   1,760,302    1,862,215    101,913 
Equity and other mutual funds   1,206,038    1,619,111    413,073 
Total marketable securities  $8,933,945   $9,448,931   $514,986 

 

December 31, 2018 (audited)         
          
U.S Treasury Bills (Original maturities greater than three months, but less than one year)  $3,742,681   $3,742,681   $—   
Fixed income mutual funds   2,408,799    2,409,213    414 
Equity and other mutual funds   1,218,153    1,470,302    252,149 
Total marketable securities  $7,369,633   $7,622,196   $252,563 

 

Page 10 of 22

 

 

Investment income is recognized when earned and consists principally of interest income from fixed income mutual funds and U.S Treasury Bills, and dividend income from equity and other mutual funds. The U.S. Treasury Bills are considered debt securities, and as such, any unrealized gains and losses are reported in other comprehensive income.  Unrealized gains and losses from the Company’s mutual fund equity securities are recognized in net income. Realized gains and losses on sales of investments are determined on a specific identification basis.

 

Proceeds from the sale and redemption of marketable securities amounted to $4,480,373 for the first quarter of 2019, which includes a net loss on sales of $5,229. There were no sales or redemptions of marketable securities in the first quarter of 2018.

 

6.Inventories

 

   March 31,
2019
  December 31,
2018
   (Unaudited)  (Audited)
Inventories consist of the following:          
Raw materials  $390,743   $467,842 
Work in process   67,118    30,057 
Finished products   866,910    984,252 
Total Inventories  $1,324,771   $1,482,151 

 

Inventories are valued at the lower of cost and net realizable value. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out (“FIFO”) method. Finished product inventories at March 31, 2019 and December 31, 2018 are stated net of a reserve of $20,000, for each period, for slow moving and obsolete inventory. At March 31, 2019 and December 31, 2018, the Company had an allowance of $186,469 and $160,533 respectively, for possible outdated material returns.

 

7.Income Taxes

 

The Company’s tax provision is based on its estimated annual effective tax rate. The Company continues to fully recognize its tax benefits, and as of March 31, 2019 and December 31, 2018, the Company did not have any unrecognized tax benefits. The Company’s provision for income taxes for the three months ended March 31 comprises the following:

 

   Three-month period ended
   March 31, 2019  March 31, 2018
Provision for federal income taxes - current  $314,163   $310,117 
Provision for federal income taxes - deferred   10,856    (28,381)
Total provision for income taxes  $325,019   $281,736 

 

8.Defined Contribution Plan

 

The Company sponsors a 401(k) defined contribution plan (“DC Plan”) that provides for a dollar-for-dollar employer matching contribution of the first 4% of each employee’s pay that is deferred by the employee. Employees become fully vested in employer matching contributions after one year of employment.

 

Page 11 of 22

 

 

The Company also makes discretionary contributions to each employee's account based on a "pay-to-pay" safe-harbor formula that qualifies the 401(k) Plan under current IRS regulations. For the year ended December 31, 2019 the Company’s Board of Directors authorized discretionary contributions in the amount of $150,000 per year to be allocated among all eligible employees. For the year ended December 31, 2018, the Company’s Board of Directors authorized $175,000 to be allocated among all eligible employees, before being subsequently reduced to $145,000. Employees become vested in the discretionary contributions as follows: 20% after two years of employment, and 20% for each year of employment thereafter until the employee becomes fully vested after six years of employment. The Company accrued $37,500 in contributions to the DC Plan for the three-month period ended March 31, 2019 and $43,750 for the three-month period ended March 31, 2018. For the first quarters of 2019 and 2018 the Company did not make any discretionary contributions to the DC Plan.

 

9.Other Information

 

Accrued Expenses

 

   March 31, 2019  December 31, 2018
   (unaudited)  (audited)
Bonuses  $363,000   $242,000 
Distribution fees   316,822    315,242 
Payroll and related expenses   189,354    159,385 
Reserve for outdated material   186,469    160,533 
Audit fee   22,250    43,668 
Computer services   7,418    16,593 
Insurance   79,351    —   
Annual report expenses   35,627    66,618 
Company 401K contribution   37,500    —   
Sales rebates   18,500    15,000 
Other   20,660    21,596 
Total Accrued Expenses  $1,276,951   $1,040,635 

 

10.Recent Accounting Pronouncements

 

Effective January 1, 2018, the Company adopted ASC Topic 606 “Revenue from Contracts with Customers”, using the modified retrospective method. This guidance supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of the guidance is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods and services. The Company has drafted its accounting policy for the new standard based on a detailed review of its business and contracts. Based on the new guidance, the Company expects to continue to recognize revenue at the time its products are shipped, and therefore, adoption of this standard did not have a material impact on its financial statements.

 

Page 12 of 22

 

 

Effective January 2018, the Company adopted Accounting Standards Update (“ASU”) 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities”. This amendment requires companies to measure equity investments at fair value with the changes in fair value recognized in net income. In accordance with the implementation of the standard, the Company made a cumulative-effect adjustment to increase retained earnings and decrease accumulated other comprehensive income as of January 1, 2018 in the amount of $466,025 to reflect the cumulative unrealized gains recorded as of that date.

 

In January 2019, the Company adopted ASU 2016-02, “Leases”, which is intended to improve financial reporting for lease transactions. This ASU requires organizations that lease assets, such as real estate and manufacturing equipment, to recognize both assets and liabilities on their balance sheet for the rights to use those assets for the lease term and obligations to make the lease payments created by those leases that have terms of greater than 12 months. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as finance or operating lease. This ASU requires disclosures to help investors and other financial statement users better understand the amount and timing of cash flows arising from leases. The disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the financial statements. The adoption of this standard did not have a material impact on the Company’s financial statements.

 

In June 2016, the FASB issued ASU-2016-13 “Financial Instruments – Credit Losses”. This guidance affects organizations that hold financial assets and net investments in leases that are not accounted for at fair value with changes in fair value reported in net income. The guidance requires organizations to measure all expected credit losses for financial instruments at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. It is effective for fiscal years beginning after December 15, 2019. The Company is evaluating the potential impact on its financial statements.

 

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement” (Topic 820), Changes to the Disclosure Requirements for Fair Value Measurement”. This amendment’s objective is to improve the effectiveness of disclosures about recurring or nonrecurring fair value measurements. This amendment is effective for fiscal years beginning after December 15, 2019. The Company is evaluating the potential impact this standard may have on its financial statements.

 

11.Concentrations of Credit Risk

 

Cash and cash equivalents: For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months or less at inception. The Company deposits cash and cash equivalents with high credit quality financial institutions and believes that any amounts in excess of insurance limitations to be at minimal risk. Cash and cash equivalents held in these accounts are currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to a maximum of $250,000. At March 31, 2019, approximately $314,000 exceeded the FDIC limit.

 

Customer concentration: Accounts receivable potentially exposes the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history to determine how much credit to allow or whether any credit should be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its credit risk from accounts receivable is low.

 

Page 13 of 22

 

 

For the three months ended March 31, 2019 one of the Company’s distributors and one of its marketing partners together accounted for 55% of the Company’s gross sales, and 51% of its outstanding accounts receivable at March 31, 2019. During the three-month period ended March 31, 2018, the same distributor and marketing partner together were responsible for a total of approximately 57% of the Company’s net sales. They also accounted for 57% of the Company’s outstanding accounts receivable at March 31, 2018.

 

12.Earnings Per Share

 

Basic earnings per share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities had been issued.

 

Per share basic and diluted earnings amounted to $0.27 and $0.23 for the three months ended March 31, 2019 and 2018, respectively.

 

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

 

FORWARD-LOOKING STATEMENTS

 

Statements made in this Form 10-Q which are not purely historical are forward-looking statements with respect to the goals, plans, objectives, intentions, expectations, financial condition, results of operations, future performance and business of the Company. Forward-looking statements may be identified using such words as "believes," "may," "will," "should," "intends," "plans," "estimates," or "anticipates" or other similar expressions.

 

Forward-looking statements involve inherent risks and uncertainties, and important factors (many of which are beyond our control) could cause actual results to differ materially from those set forth in the forward-looking statements. In addition to those specific risks and uncertainties set forth in the Company's reports currently on file with the SEC, some other factors that may affect the future results of operations of the Company are: the development of products that may be superior to those of the Company; changes in the quality or composition of the Company's products; lack of market acceptance of the Company's products; the Company's ability to develop new products; general economic or industry conditions; changes in intellectual property rights; changes in interest rates; new legislation or regulatory requirements; conditions of the securities markets; the Company's ability to raise capital; changes in accounting principles, policies or guidelines; financial or political instability; acts of war or terrorism; and other economic, competitive, governmental, regulatory and technical factors that may affect the Company's operations, products, services and prices.

 

Page 14 of 22

 

 

Accordingly, results achieved may differ materially from those anticipated as a result of such forward-looking statements, and those statements speak only as of the date they are made.

 

The Company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements.

 

OVERVIEW

 

The Company is a Delaware corporation that, through its Guardian Laboratories division, conducts research, product development, manufacturing and marketing of cosmetic ingredients, personal and health care products, pharmaceuticals, medical products, and proprietary specialty industrial products. All the products that the Company manufactures, with the exception of Renacidin®, are produced at its facility in Hauppauge, New York, and are marketed through marketing partners, distributors, wholesalers, direct advertising, mailings, and trade exhibitions. Its most important product line is its Lubrajel® line of water-based moisturizing and lubricating gels, which are used primarily as ingredients in cosmetic products. The Company’s research and development department is actively working on the development of new products to expand the Company’s line of personal care products. Many of the Company’s products use proprietary manufacturing processes, and the company relies primarily on trade secret protection to protect its intellectual property.

 

The Company’s personal care products are marketed worldwide by six marketing partners, the largest of which is U.S.-based ASI. The Company also sells two pharmaceutical products for urological uses. Those products are sold primarily in the United States through the major drug wholesalers, which in turn sell the products to pharmacies, hospitals, nursing homes and other long-term care facilities, and to government agencies, primarily the VA.

 

The Company’s non-pharmaceutical medical products (referred to hereinafter as “medical products”), such as its catheter lubricants, as well as its specialty industrial products, are sold directly by the Company to the end users or to contract manufacturers utilized by the end users, although they are available for sale on a non-exclusive basis by its marketing partners as well.

 

While the Company does have competition in the marketplace for some of its products, particularly its cosmetic ingredients, some of its pharmaceutical and medical products have some unique characteristics, and do not have direct competitors. However, these products may have indirect competition from other products that are not marketed as direct competitors to the Company’s products but may have functionality or properties that are similar to the Company’s products.

 

The Company recognizes revenue when products are shipped, title and risk of loss pass to the customers, persuasive evidence of a sales arrangement exists, and collections are reasonably assured. An allowance for returns, based on historical experience, is taken as a reduction of sales within the same period the revenue is recognized.

 

Page 15 of 22

 

 

Over the years the Company has been issued many patents and trademarks, and it still maintains a number of registered trademarks, the two most important of which are “Lubrajel” and “Renacidin”. However, in regard to protection of the Company’s proprietary formulations and manufacturing technology the Company currently relies primarily on trade secret protection rather than patent protection due to the current disclosure requirements needed to obtain patents, the limited protection they afford, and the difficulty and expense of enforcing them. However, the Company may, from time to time, seek patent protection when it believes it would be in the Company’s best interest to do so. All of the Company’s previously-issued patents have expired; however, the Company does not believe that the expiration of those patents has had, or will have, any material impact on its sales, since in recent years protection for the Company’s most important products has been based on trade secrets and proprietary manufacturing methods rather than patent protection.

 

Critical Accounting Policies

 

As disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, the discussion and analysis of the Company’s financial condition and results of operations are based on its financial statements, which have been prepared in conformity with US GAAP. The preparation of those financial statements required the Company to make estimates and assumptions that affect the carrying value of assets, liabilities, revenues and expenses reported in those financial statements. Those estimates and assumptions can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company’s most critical accounting policies relate to revenue recognition, concentration of credit risk, investments, inventory, and income taxes. Since December 31, 2018, there have been no significant changes to the assumptions and estimates related to those critical accounting policies.

 

The following discussion and analysis covers material changes in the financial condition of the Company since the year ended December 31, 2018, and a comparison of the results of operations for the three months ended March 31, 2019 and March 31, 2018. This discussion and analysis should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in the Company's Annual Report on Form 10-K for the year ended December 31, 2018. All references in this quarterly report to “sales” or “Sales” shall mean Gross Sales.

 

The Company recognizes revenue from sales of its personal care, medical, and industrial products when those products are shipped, as long as a valid purchase order has been received and future collection of the sale amount is reasonably assured. These products are shipped “Ex-Works” from the Company’s facility in Hauppauge, NY, and it is at this time that risk of loss and responsibility for the shipment passes to the customer. Sales of these products are deemed final, and there is no obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective.

 

The Company’s pharmaceutical products are shipped via common carrier upon receipt of a valid purchase order, with, in most cases, the Company paying the shipping costs. The Company assumes responsibility for the shipment arriving at its intended destination. Sales of pharmaceutical products are final and revenue is recognized at the time of shipment. Pharmaceutical products are returnable only at the discretion of the Company unless (a) they are found to be defective; (b) the product is damaged in shipping; or (c) the product is outdated (but not more than one year after their expiration date, which is a return policy which conforms to standard pharmaceutical industry practice). The Company estimates an allowance for outdated material returns based on gross sales of their pharmaceutical products.

 

Page 16 of 22

 

 

RESULTS OF OPERATIONS

 

Gross Sales

 

Gross sales for the first quarter of 2019 decreased by $214,053 (approximately 6%) as compared with the first quarter of 2018. The decrease in sales for the three-month period ended March 31, 2019 was primarily attributable to a decrease in sales of the Company’s personal care products, which was partially offset by increased sales of the Company’s pharmaceutical and medical products. Sales of the Company’s industrial products did not materially change compared with the first quarter of 2018. The changes in the sales of the products in the Company’s different products lines were as follows:

 

(a)Personal care products: Sales of the Company’s personal care products decreased by $471,392 (approximately 22%) when compared with the same period in 2018. The decrease was primarily attributable to a decrease in purchases of the Company’s cosmetic ingredients by both ASI, whose purchases declined by $286,477 (approximately 17%) compared with the same period in 2018, and C&M International, the Company’s distributor in South Korea, whose purchases decreased by $156,693 (approximately 92%) compared with the first quarter of 2018.

 

Based on information provided to the Company by ASI , the decrease in purchases by ASI in the first quarter of 2019 compared with the first quarter of 2018 was primary attributable to reduced demand for product in both North America and China. Those decreases were primarily due to a) reduced customer demand for some of the retail products in which our products are being used; b) customer ordering patterns that can sometimes distort sales due to product launches and pipeline fills that have short term impacts on sales; and c) the phasing in by some customers of a change from one grade of the Company’s products to a different grade. In the first quarter of 2018 there were some new product launches that resulted in pipeline fills that accounted for some increased demand in that quarter, with subsequent demand being lower after the initial product launch. This was not the case in the first quarter of 2019. While competition from lower-cost products from Asian manufacturers is still a potential obstacle to increasing the Company’s sales, the information we received from ASI indicates that substitution of competitive products for ours was not a significant factor in the decline in personal care products sales that we experienced in the first quarter. Notwithstanding the competition from the lower-cost products, the Company intends to continue to aggressively compete in these markets whenever it is practical to do so. It also hopes to increase its sales in China through the development of additional products that would have distinctive properties from the Company’s current line of products.”

 

Based on information provided to the Company by its marketing partner for South Korea, the decrease in sales of the Company’s products in South Korea has been due to trade issues that are preventing some South Korean products from being marketed in China. This resulted in a significant decline in that marketing partner’s purchases from the Company in the first quarter of 2019 compared with the same period in 2018. The Company has been looking further into this situation, and is evaluating its options to increase its sales in South Korea.

 

Sales of the Company’s personal care products to the Company’s four other marketing partners, all in Europe, decreased by $29,868 (approximately 11%). Sales to the Company’s marketing partners in the UK and Italy decreased by a total of $34,143 (approximately 20%) compared with their sales in the first quarter of 2018, while sales to the Company’s marketing partners in Switzerland and France increased by a total of $4,275 (approximately 4%) compared with their sales in the first quarter of 2018. In addition to the increases and decreases in sales attributable to the four European marketing partners there was a small sale of $1,645 directly to a personal care customer in the United States, bringing the total decrease in personal care product sales to $471,392.

 

Page 17 of 22

 

 

The sales fluctuations to the Company’s four European marketing partners are the result of both the timing of customer orders as well as continuing competition from companies selling competitive products at lower prices, particularly a number of Asian manufacturers. This has resulted in a loss of some business in Europe to these less expensive products. As a result, from time to time the Company has adjusted its prices in order to retain or attract customers and be more competitive with some of the lower-priced products. Although there has been some impact on the Company’s profit margins on those sales, to date this impact has not been significant. The Company intends to continue to aggressively compete with these products whenever possible.

 

(b)Pharmaceuticals: Pharmaceutical sales increased by $184,763 (approximately 19%) in the first quarter of 2019 compared with the same period in 2018. This increase was due primarily to an increase of $173,196 (approximately 20%) in Renacidin sales. Sales of the Company’s other pharmaceutical product, Clorpactin WCS-90, increased by $11,567 (approximately 9%) primarily due to the timing of orders.

 

(c)Medical (non-pharmaceutical) products: Sales of medical products increased by $71,332 (approximately 13%) for the first quarter of 2019 when compared with the same period in 2018. The increase was primarily due to the ordering patterns of customers.

 

(d)Industrial and other products: Sales of specialty industrial products, as well as other miscellaneous products, increased by $1,244 (less than 1%) for the first quarter of 2019 compared with the same period in 2018.

 

In addition to the above changes in sales, sales allowances and returns increased by $23,435 (approximately 16%) for the first quarter of 2019 when compared with the same period in 2018. This increase was primarily due to increases in allowances for outdated material returns and chargebacks from the VA, Medicaid, and Medicare .

 

Cost of Sales

 

Cost of sales as a percentage of net sales increased to approximately 42% for the first quarter of 2019, up from approximately 41% for the first quarter in 2018. The increase was primarily the result of the increase in sales of Renacidin, which carries a higher cost to manufacture than some of the Company’s other products.

 

Operating Expenses

 

Operating expenses, consisting of selling, general, and administrative expenses, increased by $22,848 (approximately 4%) for the first quarter of 2019 compared with the first quarter of 2018. The increase was mainly due to increases in computer services and insurance expenses.

 

Page 18 of 22

 

 

Research and Development Expenses

 

Research and development expenses decreased by $3,005 (approximately 3%) for the first quarter of 2019 compared with the first quarter of 2018. The decrease was due to decreases in payroll and payroll-related expenses.

 

Investment Income

 

Investment income decreased by $2,615 (approximately 6%) for the first quarter of 2019 compared with the first quarter of 2018. This is due to a decrease in investment income from stock and bond mutual funds and U.S. treasury bills.

 

Net Gain on Marketable Securities

 

Net gain on marketable securities increased by $392,344 (approximately 290%) for the first quarter of 2019 compared with the first quarter of 2018. This is due to the Company recognizing a loss of $135,150 in the first quarter of 2018, compared with a gain of $257,194 in the first quarter of 2019 due to current market conditions.

 

Provision for Income Taxes

 

The Company's effective income tax rate was approximately 21% for the first quarter of 2019 and 2018. The Company’s tax rate is expected to remain at 21% for the current fiscal year.

 

LIQUIDITY AND CAPITAL RESOURCES

 

Working capital increased by $1,262,663 to $11,583,612 at March 31, 2019, up from $10,320,949 at December 31, 2018. The increase in working capital was primarily due to increases in marketable securities. The current ratio decreased to 8.4 to 1 at March 31, 2019, down from 8.6 to 1 at December 31, 2018. The decrease in the current ratio was primarily due to an increase in accrued expenses.

 

The Company believes that its working capital is, and will continue to be, sufficient to support its operating requirements for at least the next twelve months. The Company does not expect to incur any material capital expenditures for the remainder of 2019.

 

The Company generated cash from operations of $1,531,654 and $1,670,181 for the three months ended March 31, 2019 and March 31, 2018, respectively. The decrease was primarily due to the timing of estimated tax payments made in 2019 compared with 2018.

 

Cash used in investing activities for the three-month period ended March 31, 2019 was $1,582,533, compared with $1,323,754 for the three-month period ended March 31, 2018. The increase was primarily due to an increase in the amount of marketable securities purchased in the first quarter of 2019 compared with the first quarter of 2018.

 

Page 19 of 22

 

 

There was no cash used in financing activities for the first quarters of 2019 and 2018.

 

The Company expects to continue to use its cash to make dividend payments, purchase marketable securities, and take advantage of other market opportunities that may arise that are in the best interests of the Company and its shareholders.

 

OFF BALANCE SHEET-ARRANGEMENTS

 

The Company has no off balance-sheet transactions that have, or are reasonably likely to have, a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

CONTRACTUAL OBLIGATIONS AND COMMITMENTS

 

The information to be reported under this item is not required of smaller reporting companies.

 

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

The information to be reported under this item is not required of smaller reporting companies.

 

Item 4. CONTROLS AND PROCEDURES

 

(a)DISCLOSURE CONTROLS AND PROCEDURES

 

The Company’s management, including its Principal Executive Officer and Principal Financial Officer, has evaluated the design, operation, and effectiveness of the Company’s disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934 (the “Exchange Act”). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon the evaluation performed by the Company’s management, including its Principal Executive Officer and Principal Financial Officer, it was determined that, as of the end of the period covered by this quarterly report, the Company’s disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed in the reports filed or submitted pursuant to the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Principal Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding disclosures.

 

Page 20 of 22

 

 

(b)CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

 

The Company's Principal Executive Officer and Principal Financial Officer have determined that, during the period covered by this quarterly report, there were no changes in the Company's internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting. They have also concluded that there were no significant changes in the Company’s internal controls after the date of the evaluation.

 

PART II - OTHER INFORMATION

 

 

ITEM 1.LEGAL PROCEEDINGS

 

None

 

ITEM 1A.RISK FACTORS

 

The information to be reported under this item is not required of smaller reporting companies.

 

ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None       

 

ITEM 3.DEFAULTS UPON SENIOR SECURITIES

 

None

 

ITEM 4.MINE SAFETY DISCLOSURES

 

None

 

ITEM 5.OTHER INFORMATION

 

None

 

ITEM 6.EXHIBITS

 

  31.1 Certification of Kenneth H. Globus, President and Principal Executive Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
  31.2 Certification of Andrea J. Young, Chief Financial Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
  32 Certifications of Principal Executive Officer and Chief Financial Officer of the Company, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

Page 21 of 22

 

 

SIGNATURES

 

In accordance with the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  UNITED-GUARDIAN, INC.  
  (Registrant)  
       
  By: /S/ KENNETH H. GLOBUS  
    Kenneth H. Globus  
    President  
       
  By: /S/ ANDREA J. YOUNG  
    Andrea J. Young  
    Chief Financial Officer  
Date: May 8, 2019      

 

 

 

 

 

 

 

 

Page 22 of 22